Targets for asthma therapy.
Most asthma is allergic in origin, the disease involves four distinct phases of response: the sensitization phase and the activation phase, followed by the effector phase, initiated by the release of pharmacologically active agents, the growth and repair phase, characterized by proliferation of tissues as "remodeling" of the airway wall, altering structure and function.
Boushey
H
H
Asthma Clinical Research Center, University of California, San Francisco, CA, USA.
D000485:Allergens / Q000235:genetics / Q000276:immunology; D000818:Animals; D018927:Anti-Asthmatic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D017951:Antigen Presentation / Q000187:drug effects; D001249:Asthma / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D015815:Cell Adhesion Molecules / Q000037:antagonists & inhibitors; D018899:CpG Islands; D016207:Cytokines / Q000037:antagonists & inhibitors; D018450:Disease Progression; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D011992:Endosomes / Q000187:drug effects; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007378:Interleukins / Q000037:antagonists & inhibitors; D051379:Mice; D011480:Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011817:Rabbits; D012756:Sheep; D018418:Th2 Cells / Q000187:drug effects / Q000276:immunology
D000485:Allergens; D018927:Anti-Asthmatic Agents; D015815:Cell Adhesion Molecules; D016207:Cytokines; D007378:Interleukins; D011480:Protease Inhibitors; D007073:Immunoglobulin E